Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018

References

• RiceLB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S7–10.20929376
   PubMed Web of Science ®Google Scholar
• AntunesLCS, ViscaP, TownerKJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.1212524376225
   PubMed Web of Science ®Google Scholar
• KoulentiD, TsigouE, RelloJ. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006. doi:10.1007/s10096-016-2703-z27287765
   PubMed Web of Science ®Google Scholar
• ChopraT, MarchaimD, AwaliRA, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother. 2013;57(12):6270–6275. doi:10.1128/AAC.01520-1324100492
   PubMed Web of Science ®Google Scholar
• ButlerDA, BiagiM, TanX, QasmiehS, BulmanZP, WenzlerE. Multidrug resistant acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21(12):46. doi:10.1007/s11908-019-0706-531734740
   PubMed Web of Science ®Google Scholar
• GaoL, LyuY, LiY. Trends in drug resistance of acinetobacter baumannii over a 10-year period: nationwide data from the china surveillance of antimicrobial resistance program. Chin Med J. 2017;130(6):659–664. doi:10.4103/0366-6999.20160128303847
   PubMed Web of Science ®Google Scholar
• WeinerLM, WebbAK, LimbagoB, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301. doi:10.1017/ice.2016.17427573805
   PubMed Web of Science ®Google Scholar
• MagillSS, EdwardsJR, BambergW, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208. doi:10.1056/NEJMoa130680124670166
   PubMed Web of Science ®Google Scholar
• TacconelliE, CarraraE, SavoldiA, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• ToussaintKA, GallagherJC. β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015;49(1):86–98. doi:10.1177/106002801455665225361682
   PubMed Web of Science ®Google Scholar
• OlsenI. New promising β-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis. 2015;34(7):1303–1308. doi:10.1007/s10096-015-2375-025864193
   PubMed Web of Science ®Google Scholar
• DrawzSM, Papp-WallaceKM, BonomoRA. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835–1846. doi:10.1128/AAC.00826-1324379206
   PubMed Web of Science ®Google Scholar
• MotschJ, Murta de OliveiraC, StusV, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808. doi:10.1093/cid/ciz53031400759
   PubMed Web of Science ®Google Scholar
• TitovI, WunderinkRG, RoquillyA. et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis;2020. ciaa803. doi:10.1093/cid/ciaa80332785589
   PubMed Web of Science ®Google Scholar
• LapueblaA, AbdallahM, OlafisoyeO, et al. Activity of Imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031. doi:10.1128/AAC.00830-1526014931
   PubMed Web of Science ®Google Scholar
• YoungK, RaghoobarSL, HairstonNN. In vitro Activity of the Class a and C b-Lactamase Inhibitor MK-7655. Posters of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 2010. Poster F1-2139. Washington, DC, USA: American Society for Microbiology; 2010.
   Google Scholar
• LivermoreDM, WarnerM, MushtaqS. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.23696619
   PubMed Web of Science ®Google Scholar
• LobS, HackelM, KazmierczakK, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015: results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017;88:171–176. doi:10.1016/j.diagmicrobio.2017.02.01828291628
   PubMed Web of Science ®Google Scholar
• KarlowskyJA, LobSH, KazmierczakKM, YoungK, MotylMR, SahmDF. In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the united states as part of the SMART 2016 program. Antimicrob Agents Chemother. 2018;62(7):e00169–00118. doi:10.1128/AAC.00169-1829760135
   PubMed Web of Science ®Google Scholar
• LobSH, HackelMA, KazmierczakKM, et al. In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017;61(6):e02209–02216. doi:10.1128/AAC.02209-1628320716
   PubMed Web of Science ®Google Scholar
• LobSH, KarlowskyJA, YoungK, et al. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–2017. J Antimicrob Chemother. 2019;74(8):2284–2288. doi:10.1093/jac/dkz19131086960
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 28th. CLSI M100. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• U. S. Food & Drug A. Antibacterial Susceptibility Test Interpretive Criteria. US Food and Drug Administration; 2020.
   Google Scholar
• XuY, HuoR, YanZ, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Chin J Nosocomiol. 2017;27(1):231–240.
   Google Scholar
• KarlowskyJA, LobSH, YoungK, MotylMR, SahmDF. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. J Glob Antimicrob Resist. 2018;15:140–147. doi:10.1016/j.jgar.2018.07.01230071354
   PubMed Web of Science ®Google Scholar
• YinD, WuS, YangY, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.02431-18.
   Web of Science ®Google Scholar
• KarlowskyJA, LobSH, KazmierczakKM, et al. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018;73(7):1872–1879. doi:10.1093/jac/dky10729659861
   PubMed Web of Science ®Google Scholar
• HanL, LeiJ, XuJ, HanS. blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a high level of carbapenem resistance in Acinetobacter baumannii strains from a teaching hospital in Xi’an, China. Medicine. 2017;96(48):e8965. doi:10.1097/MD.000000000000896529310399
   PubMed Web of Science ®Google Scholar
• Rodríguez-BeltránJ, CabotG, ValenciaEY, et al. N-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism. Antimicrob Agents Chemother. 2015;59(6):3246–3251. doi:10.1128/AAC.00017-1525801561
   PubMed Web of Science ®Google Scholar
• PoirelL, NordmannP. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12(9):826–836. doi:10.1111/j.1469-0691.2006.01456.x16882287
   PubMed Web of Science ®Google Scholar
• SewardRJ, LambertT, TownerKJ. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J Med Microbiol. 1998;47(5):455–462. doi:10.1099/00222615-47-5-4559879947
   PubMed Web of Science ®Google Scholar
• FalagasME, KasiakouSK, SaravolatzLD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341. doi:10.1086/42932315825037
   PubMed Web of Science ®Google Scholar
• TosiM, RoatE, De BiasiS, et al. Multidrug resistant bacteria in critically ill patients: a step further antibiotic therapy. J Emerg Crit Care Med. 2018;2:103. doi:10.21037/jeccm.2018.11.08
   Google Scholar
• WielandK, ChhatwalP, VonbergRP. Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa: results of a systematic review. Am J Infect Control. 2018;46(6):643–648. doi:10.1016/j.ajic.2017.12.01429398072
   PubMed Web of Science ®Google Scholar
• McCannE, SrinivasanA, DeRykeCA, et al. Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in us hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5(10):ofy241. doi:10.1093/ofid/ofy24130364442
   PubMed Web of Science ®Google Scholar
• XuY, NiuH, HuT, et al. High expression of metallo-β-lactamase contributed to the resistance to carbapenem in clinical isolates of pseudomonas aeruginosa from Baotou, China. Infect Drug Resist. 2020;13:35–43. doi:10.2147/IDR.S23398732021318
   PubMed Web of Science ®Google Scholar
• FanX, WuY, XiaoM, et al. Diverse Genetic background of multidrug-resistant pseudomonas aeruginosa from mainland china and emergence of an extensively drug-resistant ST292 clone in kunming. Sci Rep. 2016;6(1):26522. doi:10.1038/srep2652227198004
   PubMed Web of Science ®Google Scholar
• TselepisL, LangleyGW, AboklaishAF, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(1):105925. doi:10.1016/j.ijantimicag.2020.10592532084512
   PubMed Web of Science ®Google Scholar